Tarsus Pharmaceuticals, Inc.
TARS
$69.16
$0.280.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 173.91M | 162.05M | 151.67M | 118.70M | 102.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 173.91M | 162.05M | 151.67M | 118.70M | 102.66M |
| Cost of Revenue | 12.11M | 31.75M | 28.96M | 24.59M | 6.24M |
| Gross Profit | 161.80M | 130.31M | 122.71M | 94.10M | 96.42M |
| SG&A Expenses | 150.70M | 136.43M | 130.68M | 108.63M | 103.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 193.82M | 168.18M | 159.64M | 133.23M | 124.84M |
| Operating Income | -19.91M | -6.12M | -7.98M | -14.53M | -22.18M |
| Income Before Tax | -15.84M | -4.62M | -6.31M | -12.59M | -20.34M |
| Income Tax Expenses | 2.72M | 2.35M | 2.06M | -- | -- |
| Earnings from Continuing Operations | -18.55M | -6.97M | -8.37M | -12.59M | -20.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.55M | -6.97M | -8.37M | -12.59M | -20.34M |
| EBIT | -19.91M | -6.12M | -7.98M | -14.53M | -22.18M |
| EBITDA | -18.91M | -5.69M | -7.53M | -14.07M | -21.73M |
| EPS Basic | -0.43 | -0.16 | -0.20 | -0.30 | -0.48 |
| Normalized Basic EPS | -0.27 | -0.08 | -0.03 | -0.18 | -0.30 |
| EPS Diluted | -0.43 | -0.16 | -0.20 | -0.30 | -0.48 |
| Normalized Diluted EPS | -0.27 | -0.08 | -0.03 | -0.18 | -0.30 |
| Average Basic Shares Outstanding | 43.39M | 42.96M | 42.78M | 42.61M | 42.36M |
| Average Diluted Shares Outstanding | 43.39M | 42.96M | 42.78M | 42.61M | 42.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |